The Neuropsychiatric Drug Development Summit annually unites 150+ biotech and pharma stakeholders, with functions spanning discovery, in vivo pharmacology, translational medicine, clinical development, medical, regulatory affairs and more, as well as leading academics, venture capitalists and solution providers, in one hyper-relevant and focused setting.
Across the 3 days, attendees engaged in deep-dive interactive workshops, roundtable discussions, data-driven presentations and structured networking activities to foster collaboration and gain the most recent insights to truly advance your pipeline of next generation neuropsychiatric therapeutics.
What Was New for 2025?
EEG Biomarker Seminar Day
Optimizing the use of EEG as a comprehensive & translational tool to guide your program through end-to-end development
Investor's Panel
Exploring the catalysts driving deal-making momentum in neuropsychiatry and discover what investors are seeking from the next wave of readouts
Brand-New Presenting Companies
Including Reunion Neuroscience, Intra-Cellular Therapies, Seaport Therapeutics, Cybin, Kinoxis Therapeutics and many more
View the 2025 Full Event Guide
- Learn more about 2025's 40+ expert speakers
- Discover the EEG Focus Day & Investor's Panel
- Uncover the latest developments spanning depression, schizophrenia, anxiety, addiction and more
- See who attended the 2025 meeting
Who Did You Meet?
What Your Peers Had to Say
“I thought the topics of discussion were very timely and pertinent. I enjoyed the diversity of content through combination of large group talks, panel discussions, small seminars and roundtable discussions.”
Director, Alkermes
“Great to have so many pharma experts reunited to discuss bottle necks of neuropsychiatry R&D.”
External Innovation Manager, Boehringer Ingelheim